Summary: Week of 12/30/24
Biobot’s national wastewater network shows that SARS-CoV-2 and influenza A & B continue to increase, while RSV has started decreasing in week 52 (through December 28, 2024). National hospitalizations for COVID-19 and RSV are holding steady, currently at 2.3 and 2.7 per 100,000 people in week 51 (through December 21, 2024), respectively. National hospitalizations for influenza continue to increase and are the highest compared to the other respiratory viruses, currently at 3.5 per 100,000 people.
The Bottom Line: COVID-19, RSV, and influenza remain high, with flu causing the most burden. It’s good to remember these recommendations to stay healthy: stay current with vaccinations and boosters, consider wearing a mask in crowded areas, and if you feel unwell, minimize contact with others.
National Outlook
COVID-19
National SARS-CoV-2 concentrations are increasing.
Influenza
National influenza A and B concentrations are increasing.
RSV
National RSV concentrations are holding steady.
Regional
The South
COVID-19: SARS-CoV-2 concentrations are increasing in the South.
Influenza: Influenza A concentrations are decreasing in the South, while influenza B is increasing.
RSV: RSV concentrations are decreasing in the South.
The Midwest
COVID-19: SARS-CoV-2 concentrations are increasing in the Midwest.
Influenza: Influenza A and B concentrations are increasing in the Midwest.
RSV: RSV concentrations are increasing in the Midwest.
The Northeast
COVID-19: SARS-CoV-2 concentrations are increasing in the Northeast.
Influenza: Influenza A and B concentrations are increasing in the Northeast.
RSV: RSV concentrations are decreasing in the Northeast.
The West
COVID-19: SARS-CoV-2 concentrations are increasing in the West.
Influenza: Influenza A and B concentrations are increasing in the West.
RSV: RSV concentrations are increasing in the West.
Footnotes:
We continue to monitor the evolving H5N1 influenza virus situation, and can now test samples specifically for H5 (including H5N1) — please reach out to hello@biobot.io if interested. A quick reminder that Biobot’s influenza A assay described in this report includes the H5N1 influenza subtype, which is an influenza A virus, but does not distinguish between the different subtypes of influenza A (e.g. H5N1 vs H1N1). We will share any important updates as we have them via Twitter and Bluesky, and in the risk reports.
Wastewater data from Biobot Analytics for RSV, influenza, and SARS-CoV-2 are through December 28, 2024 (MMWR week 52). Clinical data for RSV, influenza, and COVID-19 are from the Centers for Disease Control and Prevention. Updates to clinical data are through December 21, 2024 (MMWR week 51).